Breaking News Instant updates and real-time market news.

GLPG

Galapagos NV

$57.96

-1.25 (-2.11%)

, GILD

Gilead

$74.46

-0.52 (-0.69%)

16:03
11/22/16
11/22
16:03
11/22/16
16:03

Galapagos reports 1st patient dosing in DIVERSITY Phase 3 study

Galapagos (GLPG) reports the first dosing of a patient in the DIVERSITY Phase 3 study with filgotinib in Crohn's disease (CD). The start of the DIVERSITY study triggers a $50 million milestone payment from Gilead (GILD) The worldwide DIVERSITY Phase 3 study will investigate efficacy and safety of 100 mg and 200 mg filgotinib once-daily compared to placebo in 1,320 patients with moderately to severely active Crohn's disease, including those with prior biological therapy failure. "With the FITZROY Phase 2 study, Galapagos demonstrated that filgotinib has a promising efficacy and safety profile in Crohn's disease. The start of the Phase 3 DIVERSITY study is good news for patients with Crohn's disease," said Dr Piet Wigerinck, CSO of Galapagos. "We look forward to seeing the results of DIVERSITY."Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. In addition to the DIVERSITY study, Gilead initiated the FINCH Phase 3 program in rheumatoid arthritis in August 2016 and is expected to start the SELECTION Phase 2b/3 study in ulcerative colitis later this quarter. Filgotinib is an investigational drug and its efficacy and safety have not been established.

GLPG

Galapagos NV

$57.96

-1.25 (-2.11%)

GILD

Gilead

$74.46

-0.52 (-0.69%)

  • 29

    Nov

  • 30

    Nov

  • 14

    Dec

GLPG Galapagos NV
$57.96

-1.25 (-2.11%)

10/12/16
RBCM
10/12/16
NO CHANGE
RBCM
Outperform
Vertex competitor to report data soon, but has long way to go, says RBC Capital
RBC Capital analyst Michael Yee noted that Galapagos NV (GLPG) and partner AbbVie (ABBV) are likely to present new Phase IIa data for GLP-1837 for cystic fibrosis and host an analyst event on October 27, adding that he believes the data will likely be positive and suggest they are "on track" with progress on their triple pill. Yee adds it won't be surprising if Galapagos has positive '1837 "potentiator" data, as this is the easier of the components and only the first piece of a 3-pill drug. Vertex (VRTX) is also hosting an analyst event on Oct. 27 and will probably also give an update on its own "triple," said Yee, who thinks it should stay in the lead with most advanced triple. Yee keeps an Outperform rating on Vertex shares.
10/18/16
GSCO
10/18/16
UPGRADE
GSCO
Buy
Galapagos NV upgraded to Buy from Neutral at Goldman
10/27/16
JEFF
10/27/16
NO CHANGE
Target $102
JEFF
Buy
Jefferies sees Galapagos as reducing competitive concerns for Vertex
Jefferies analyst Brian Abrahams believes the "difficult to interpret" data from Galapagos (GLPG) should help reduce the "overdone" competitive concerns weighing on shares of Vertex Pharmaceuticals (VRTX). Galapagos' data for GLPG1837 show "possible signals of activity, but short study, small sample size, underdosing, and variability makes the results very difficult to conclusively interpret," Abrahams tells investors in a research note. The North American Cystic Fibrosis Conference highlights the early stage of any potential competitor and Vertex's "significant developmental lead time," the analyst contends. He reiterates a Buy rating on the shares with a $102 price target.
11/01/16
WBLR
11/01/16
DOWNGRADE
Target $81
WBLR
Market Perform
William Blair downgrades Vertex with competition looming
William Blair analyst Y. Katherine Xu downgraded Vertex Pharmaceuticals (VRTX) to Market Perform from Outperform after attending the North American Cystic Fibrosis Conference. Looming competition "has become more and more real," Xu tells investors in a research note. The triple combo in vitro data from Vertex, AbbVie (ABBV)/Galapagos (GLPG) and Proteostasis (PTI) appear comparable, Xu contends. The analyst expects "deteriorating pricing" for the Vertex's Cystic Fibrosis franchise starting in 2022 due to competition. She lowered her price target for the shares to $81 from $105. Vertex closed yesterday at $78.86.
GILD Gilead
$74.46

-0.52 (-0.69%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $89
LEER
Market Perform
Gilead myelofibrosis data miss may open path for M&A, says Leerink
Leerink analyst Geoffrey Porges notes that Gilead (GILD) released disappointing Phase III data for its JAK 1/2 inhibitor momelotinib in myelofibrosis. The company indicated that they plan to discuss these results with regulatory authorities to determine the next steps, but it seems likely that momelotinib will be written off, he adds. However, Porges believes that this disappointment restores Incyte (INCY) to the list of feasible candidates for acquisition by Gilead, since it would no longer face the obligation to divest one of the overlapping JAK programs. He reiterates a Market Perform rating and $89 price target on Gilead's shares.
11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

RNECY

Renesas

$4.14

-0.17 (-3.94%)

, ISIL

Intersil

19:04
02/24/17
02/24
19:04
02/24/17
19:04
Hot Stocks
Renesas sees Intersil acquisition accretive to non-GAAP EPS, free cash flows »

Renesas Electronics…

RNECY

Renesas

$4.14

-0.17 (-3.94%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$173.53

1.61 (0.94%)

18:45
02/24/17
02/24
18:45
02/24/17
18:45
Conference/Events
Henry Schein management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

TWX

Time Warner

$97.28

0.6225 (0.64%)

18:38
02/24/17
02/24
18:38
02/24/17
18:38
Periodicals
Turner, Univision to win U.S. Champions League rights, Bloomberg reports »

Turner, a subsidiary of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRUE

TrueCar

$14.28

0.18 (1.28%)

18:33
02/24/17
02/24
18:33
02/24/17
18:33
Hot Stocks
TrueCar's ALG sees February total new vehicle sales 1.325M units, down 1.4% »

ALG projects total new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

GE

General Electric

$30.19

0.17 (0.57%)

18:24
02/24/17
02/24
18:24
02/24/17
18:24
Hot Stocks
GE does not see after-tax charges from GE Capital exit plan to exceed $23B »

GE said in a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CE

Celanese

$88.79

-0.88 (-0.98%)

18:02
02/24/17
02/24
18:02
02/24/17
18:02
Hot Stocks
Celanese announces vinyl acetate-based emulsions price increases in Asia »

Celanese announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ELNK

EarthLink

$5.63

-0.22 (-3.76%)

, WIN

Windstream

$7.27

-0.02 (-0.27%)

17:56
02/24/17
02/24
17:56
02/24/17
17:56
Hot Stocks
EarthLink, Windstream holders approve merger »

EarthLink (ELNK)…

ELNK

EarthLink

$5.63

-0.22 (-3.76%)

WIN

Windstream

$7.27

-0.02 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

PFE

Pfizer

$34.26

0.2 (0.59%)

17:43
02/24/17
02/24
17:43
02/24/17
17:43
Periodicals
Pfizer subpoenaed in investigation of charity connections, Bloomberg says »

Pfizer has received two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 09

    Mar

  • 17

    Mar

  • 23

    Mar

  • 01

    Apr

C

Citi

$59.56

-1.06 (-1.75%)

17:32
02/24/17
02/24
17:32
02/24/17
17:32
Hot Stocks
U.S. regulators investigating Citi over foreign hiring practices »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

FDX

FedEx

$193.11

1.93 (1.01%)

17:25
02/24/17
02/24
17:25
02/24/17
17:25
Hot Stocks
FedEx, USPS amend transportation agreement »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

URRE

Uranium Resources

$1.94

-0.09 (-4.43%)

17:21
02/24/17
02/24
17:21
02/24/17
17:21
Syndicate
Breaking Syndicate news story on Uranium Resources »

Uranium Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$153.48

0.19 (0.12%)

17:13
02/24/17
02/24
17:13
02/24/17
17:13
Hot Stocks
Raytheon awarded $1B government contract »

Raytheon Co., Woburn,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COTV

Cotiviti Holdings

$38.74

-0.06 (-0.15%)

17:06
02/24/17
02/24
17:06
02/24/17
17:06
Syndicate
Breaking Syndicate news story on Cotiviti Holdings »

Cotiviti Holdings files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

ENH

Endurance Specialty

$92.90

0.02 (0.02%)

17:05
02/24/17
02/24
17:05
02/24/17
17:05
Earnings
Endurance reports Q4 EPS 30c, may not compare to consensus $1.26 »

Reports Q4 gross premiums…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORPN

Bio Blast Pharma

$1.13

-0.0098 (-0.86%)

17:04
02/24/17
02/24
17:04
02/24/17
17:04
Syndicate
Breaking Syndicate news story on Bio Blast Pharma »

Bio Blast Pharma files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.40

0.3 (1.99%)

, PFE

Pfizer

$34.26

0.2 (0.59%)

16:44
02/24/17
02/24
16:44
02/24/17
16:44
General news
On The Fly: Stocks end week higher as rally continues »

Stocks ended the week…

MNTA

Momenta

$15.40

0.3 (1.99%)

PFE

Pfizer

$34.26

0.2 (0.59%)

STLD

Steel Dynamics

$35.59

0.07 (0.20%)

AKS

AK Steel

$8.02

-0.1 (-1.23%)

X

U.S. Steel

$37.01

-0.3 (-0.80%)

FLR

Fluor

$55.09

-0.26 (-0.47%)

GVA

Granite Construction

$53.91

0.78 (1.47%)

VMC

Vulcan Materials

$117.82

1.47 (1.26%)

PWR

Quanta Services

$37.76

0.62 (1.67%)

ACM

AECOM

$35.77

-0.58 (-1.60%)

JEC

Jacobs Engineering

$56.03

-0.07 (-0.12%)

KBR

KBR

$15.60

-0.55 (-3.41%)

CBI

CB&I

$33.87

-0.02 (-0.06%)

MTZ

MasTec

$40.10

3.05 (8.23%)

KHC

Kraft Heinz

$93.08

0.14 (0.15%)

UN

Unilever; also tag UL

$46.91

0.33 (0.71%)

UL

Unilever; also tag UN

$47.12

0.22 (0.47%)

QSR

Restaurant Brands

$55.47

-0.08 (-0.14%)

PLKI

Popeyes

TROX

Tronox

$17.40

-0.67 (-3.71%)

WMT

Wal-Mart

$72.39

1.08 (1.51%)

HD

Home Depot

$145.95

1.24 (0.86%)

CYH

Community Health

$9.22

0.32 (3.60%)

TOL

Toll Brothers

$33.74

-0.22 (-0.65%)

GRMN

Garmin

$53.03

0.72 (1.38%)

CHS

Chico's

$14.75

0.3 (2.08%)

HPQ

HP Inc.

$17.65

0.05 (0.28%)

CRI

Carter's

$90.04

2.98 (3.42%)

SQ

Square

$17.43

0.28 (1.63%)

JWN

Nordstrom

$46.46

2.52 (5.74%)

FL

Foot Locker

$75.01

6.43 (9.38%)

AAOI

Applied Optoelectronics

$45.98

8.51 (22.71%)

RH

Restoration Hardware

$31.34

6.15 (24.41%)

M

Macy's

$33.17

0.73 (2.25%)

PZZA

Papa John's

$78.70

-0.07 (-0.09%)

FSLR

First Solar

$37.90

0.71 (1.91%)

TXRH

Texas Roadhouse

$42.22

0.13 (0.31%)

TSLA

Tesla

$257.00

1.01 (0.39%)

LB

Labarge

$50.99

2.05 (4.19%)

W

Wayfair

$39.30

0.72 (1.87%)

HPE

HP Enterprise

$22.96

-1.7 (-6.89%)

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

ACIA

Acacia Communications

$54.04

-9.39 (-14.80%)

BGS

B&G Foods

$43.65

-3.25 (-6.93%)

SPLK

Splunk

$62.80

-2.1 (-3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

  • 24

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 03

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 07

    Mar

  • 09

    Mar

  • 09

    Mar

  • 14

    Mar

  • 15

    Mar

  • 17

    Mar

  • 19

    Mar

  • 21

    Mar

  • 23

    Mar

  • 23

    Mar

  • 28

    Mar

  • 01

    Apr

  • 04

    Apr

  • 05

    Apr

  • 17

    Apr

NBEV

New Age Beverages

$3.90

-0.04 (-1.02%)

16:41
02/24/17
02/24
16:41
02/24/17
16:41
Hot Stocks
Breaking Hot Stocks news story on New Age Beverages »

Park West AM reports 6.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$1.71

-0.07 (-3.93%)

16:40
02/24/17
02/24
16:40
02/24/17
16:40
Hot Stocks
Breaking Hot Stocks news story on Cytori Therapeutics »

Azaya Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMA

ADMA Biologics

$4.75

-0.03 (-0.63%)

16:40
02/24/17
02/24
16:40
02/24/17
16:40
Earnings
ADMA Biologics reports FY16 EPS ($1.61), consensus ($1.57) »

Reports FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.81

-0.68 (-1.16%)

16:38
02/24/17
02/24
16:38
02/24/17
16:38
Syndicate
Breaking Syndicate news story on Wells Fargo »

Wells Fargo files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

SHO

Sunstone Hotel

$14.71

-0.05 (-0.34%)

16:36
02/24/17
02/24
16:36
02/24/17
16:36
Syndicate
Breaking Syndicate news story on Sunstone Hotel »

Sunstone Hotel files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPHS

Trinity Place

$9.97

0.47 (4.95%)

16:36
02/24/17
02/24
16:36
02/24/17
16:36
Hot Stocks
Breaking Hot Stocks news story on Trinity Place »

Horse Island Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SO

Southern Company

$50.50

0.83 (1.67%)

16:35
02/24/17
02/24
16:35
02/24/17
16:35
Syndicate
Breaking Syndicate news story on Southern Company »

Southern Company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MENT

Mentor Graphics

, SIEGY

Siemens

$128.94

-1.35 (-1.04%)

16:35
02/24/17
02/24
16:35
02/24/17
16:35
Hot Stocks
KFTC clears pending merger of Mentor Graphics and Siemens »

According to a regulatory…

MENT

Mentor Graphics

SIEGY

Siemens

$128.94

-1.35 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

HPE

HP Enterprise

$22.96

-1.7 (-6.89%)

, JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

16:32
02/24/17
02/24
16:32
02/24/17
16:32
General news
On The Fly: Top stock stories for Friday »

Stocks opened with modest…

HPE

HP Enterprise

$22.96

-1.7 (-6.89%)

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

JWN

Nordstrom

$46.46

2.52 (5.74%)

FL

Foot Locker

$75.01

6.43 (9.38%)

RH

Restoration Hardware

$31.34

6.15 (24.41%)

ACIA

Acacia Communications

$54.04

-9.39 (-14.80%)

BGS

B&G Foods

$43.65

-3.25 (-6.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 03

    Mar

  • 19

    Mar

  • 28

    Mar

  • 04

    Apr

  • 05

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.